Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Jim Young"'
Autor:
Daniela K. van Santen, Rachel Sacks-Davis, Ashleigh Stewart, Anders Boyd, Jim Young, Marc van der Valk, Colette Smit, Andri Rauch, Dominique L. Braun, Inmaculada Jarrin, Juan Berenguer, Jeffrey V. Lazarus, Karine Lacombe, Maria-Bernarda Requena, Linda Wittkop, Olivier Leleux, Dominique Salmon, Fabrice Bonnet, Gail Matthews, Joseph S. Doyle, Tim Spelman, Marina B. Klein, Maria Prins, Jason Asselin, Mark A. Stoové, Margaret Hellard
Publikováno v:
EClinicalMedicine, Vol 56, Iss , Pp 101810- (2023)
Summary: Background: Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV) incidence through a “treatment as prevention” (TasP) effect. We assessed changes in primary HCV incidence following DAA access among people living
Externí odkaz:
https://doaj.org/article/659605e137e54320885128beb757fa9d
Autor:
Salome Dell-Kuster, Simon Lauper, Joerg Koehler, Johanna Zwimpfer, Benedikt Altermatt, Tibor Zwimpfer, Leon Zwimpfer, Jim Young, Heiner C Bucher, Alain J Nordmann
Publikováno v:
Scandinavian Journal of Work, Environment & Health, Vol 40, Iss 5, Pp 493-501 (2014)
OBJECTIVES: It is unclear to what extent assessments of work ability differ between disability claimants, their treating physicians, and multidisciplinary medical expert teams. METHODS: We compared assessments of work ability for consecutive disabili
Externí odkaz:
https://doaj.org/article/0b79931ffec044df86b9b3b3711ad13d
Autor:
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Jim Young, Mina Psichogiou, Laurence Meyer, Sylvie Ayayi, Sophie Grabar, Francois Raffi, Peter Reiss, Brian Gazzard, Mike Sharland, Félix Gutierrez, Niels Obel, Ole Kirk, José M Miro, Hansjakob Furrer, Antonella Castagna, Stéphane De Wit, Josefa Muñoz, Jesper Kjaer, Jesper Grarup, Geneviève Chêne, Heiner Bucher
Publikováno v:
PLoS Medicine, Vol 9, Iss 3, p e1001194 (2012)
BackgroundMost adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.Methods an
Externí odkaz:
https://doaj.org/article/24982624540344a1a86d373ca8d83720
Autor:
Marcel Wolbers, Abdel Babiker, Caroline Sabin, Jim Young, Maria Dorrucci, Geneviève Chêne, Cristina Mussini, Kholoud Porter, Heiner C Bucher, CASCADE Collaboration Members
Publikováno v:
PLoS Medicine, Vol 7, Iss 2, p e1000239 (2010)
CD4 cell count is a strong predictor of the subsequent risk of AIDS or death in HIV-infected patients initiating combination antiretroviral therapy (cART). It is not known whether the rate of CD4 cell decline prior to therapy is related to prognosis
Externí odkaz:
https://doaj.org/article/a226227300fe4fa59c5083b315210f64
Autor:
Mendon, Vrushali1, Jim Young2, Rotondo, Julia3, Keene, Kevin4, Rosenberg, Sam5, Kazmi, Ali Akber6, Delgoshaei, Payam7
Publikováno v:
ASHRAE Transactions. 2024, Vol. 130 Issue Part 1, p661-668. 8p.
Autor:
Marina B Klein, Jim Young, David Ortiz-Paredes, Shouao Wang, Sharon Walmsley, Alexander Wong, Valérie Martel-Laferrière, Neora Pick, Brian Conway, Jonathan Angel, Jean-Guy Baril, Chris Fraser, Bertrand Lebouché, Darrell HS Tan, Roger Sandre, Sylvie Trottier, Hansi Peiris, Jayamarx Jayaraman, Joel Singer
Publikováno v:
Patient Preference and Adherence.
Marina B Klein,1â 4 Jim Young,2 David Ortiz-Paredes,3 Shouao Wang,3 Sharon Walmsley,4,5 Alexander Wong,6 Valérie Martel-Laferrière,7 Neora Pick,8 Brian Conway,9 Jonathan Angel,10 Jean-Guy Baril,11 Chris Fraser,12 Bertrand Lebouché,3,13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b6e58f03a5f853d04f89695920e5637
https://www.dovepress.com/virological-outcomes-after-switching-to-abacavirlamivudinedolutegravir-peer-reviewed-fulltext-article-PPA
https://www.dovepress.com/virological-outcomes-after-switching-to-abacavirlamivudinedolutegravir-peer-reviewed-fulltext-article-PPA
Autor:
Jim Young, Marina B. Klein, Angel M. Mayor, H. Nina Kim, Michael A. Horberg, Richard D. Moore, Timothy R. Sterling, M. John Gill, Keri N. Althoff, Michael J. Silverberg, Kelly A. Gebo, Vincent Lo Re
Publikováno v:
Pharmacoepidemiol Drug Saf
PURPOSE Despite effective antiretroviral therapy, rates of end-stage liver disease (ESLD) remain high. It is not clear whether contemporary antiretrovirals contribute to the risk of ESLD. METHODS We included patients from cohorts with validated ESLD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0c1f8e7d601583052fa80a288c56e97
https://doi.org/10.1002/pds.5379
https://doi.org/10.1002/pds.5379
Autor:
Jim Young1,2,3 james.young2@mcgill.ca, Wong, Stanley4,5, Janjua, Naveed Z.4,5, Klein, Marina B.1,2,6
Publikováno v:
Pharmacology Research & Perspectives. Oct2020, Vol. 8 Issue 5, p1-9. 9p.
Publikováno v:
New Zealand Journal of Ecology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab98e622c28c67b6b4c3a8527af08bdf
https://doi.org/10.20417/nzjecol.46.24
https://doi.org/10.20417/nzjecol.46.24